Anti-apoptotic actions of insulin-like growth factors: Lessons from development and implications in neoplastic cell transformation

Current Pharmaceutical Design

Volumn 13, Issue 7, 2007, Pages 687-703

  Varela Nieto, Isabel ^a   Hartl, Markus ^c   Gorospe, Itziar ^a   León, Yolanda ^a,b  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Apoptosis; Cell transformation; Development; Neurogenesis; Sensory organs; Signalling; Target genes; Transcriptional control

Indexed keywords

CATHEPSIN D; CCAAT ENHANCER BINDING PROTEIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MATRIX METALLOPROTEINASE; MYC PROTEIN; PEGVISOMANT; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLO[2.3 D]PYRIMIDINE DERIVATIVE; RETROVIRUS VECTOR; SERINE PROTEINASE; SOMATOMEDIN; SOMATOMEDIN C; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CELL TYPE; DEREGULATION; GROWTH REGULATION; HUMAN; INNER EAR; NERVOUS SYSTEM; NONHUMAN; ORGANOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; EAR, INNER; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; SOMATOMEDINS; TRANSCRIPTION FACTORS;

EID: 34047130701     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780249164     Document Type: Review

References (208)

1. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997; 88(3): 347-54.
2. Vaux DL and Korsmeyer SJ. Cell death in development. Cell 1999; 96(2): 245-54.
3. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407(6805): 770-6.
4. Baehrecke EH. How death shapes life during development. Nat Rev Mol Cell Biol 2002; 3(10): 779-87.
5. Varela-Nieto I, de la Rosa EJ, Valenciano AI, Leon Y. Cell death in the nervous system: lessons from insulin and insulin-like growth factors. Mol Neurobiol 2003; 28(1): 23-50.
6. Leon Y, Sanchez-Galiano S, Gorospe I. Programmed cell death in the development of the vertebrate inner ear. Apoptosis 2004; 9(3): 255-64.
7. Patel AC, Nunez NP, Perkins SN, Barrett JC, Hursting SD. Effects of energy balance on cancer in genetically altered mice. J Nutr 2004; 134(12 Suppl): 3394S-8S.
8. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004; 4(8): 592-603.
9. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5(3): 231-7.
10. Fadeel B, Zhivotovsky B, Orrenius S. All along the watchtower: on the regulation of apoptosis regulators. FASEB J 1999; 13(13): 1647-57.
11. Tata JR. Requirement for RNA and protein synthesis for induced regression of the tadpole tail in organ culture. Dev Biol 1966; 13(1): 77-94.
12. Schwartz LM, Kosz L, Kay BK. Gene activation is required for developmentally programmed cell death. Proc Natl Acad Sci USA 1990; 87(17): 6594-8.
13. Raff MC. Social controls on cell survival and cell death. Nature 1992; 356(6368): 397-400.
14. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD, et al. Programmed cell death and the control of cell survival: lessons fromthe nervous system. Science 1993; 262(5134): 695-700.
15. Honig LS, Rosenberg RN. Apoptosis and neurologic disease. Am J Med 2000; 108(4): 317-30.
16. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281(5381): 1309-12.
17. Vieira HL, Kroemer G. Pathophysiology of mitochondrial cell death control. Cell Mol Life Sci 1999; 56(11-12): 971-6.
18. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86(1): 147-57.
19. Li XS, Chen JC, Sheikh MS, Shao ZM, Fontana JA. Retinoic acid inhibition of insulin-like growth factor I stimulation of c-fos mRNA levels in a breast carcinoma cell line. Exp Cell Res 1994; 211(1): 68-73.
20. Zou H, Li Y, Liu X, Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999; 274(17): 11549-56.
21. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999; 15: 269-90.
22. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281(5381): 1322-6.
23. Vaux DL, Weissman IL., Kim SK. Prevention of programmed cell death in Caenorhabditis elegans by human bcl-2. Science 1992; 258(5090): 1955-7.
24. Korsmeyer SJ, Yin XM, Oltvai ZN, Veis-Novack DJ, Linette GP. Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Biochim Biophys Acta 1995; 1271(1): 63-6.
25. Kinloch RA, Treherne JM, Furness LM, Hajimohamadreza I. The pharmacology of apoptosis. Trends Pharmacol Sci 1999; 20(1): 35-42.
26. McConkey DJ, Orrenius S. The role of calcium in the regulation of apoptosis. Biochem Biophys Res Commun 1997; 239(2): 357-66.
27. Aravind L, Dixit VM, Koonin EV. The domains of death: evolution of the apoptosis machinery. Trends Biochem Sci 1999; 24(2): 47-53.
28. Song Z, Steller H. Death by design: mechanism and control of apoptosis. Trends Cell Biol 1999; 9(12): M49-52.
29. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3(11): 859-68.
30. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, et al. Regulation of cell cycle progression and apoptosis by theRas/Raf/MEK/ ERK pathway. Int J Oncol 2003; 22(3): 469-80.
31. Hannun YA, Obeid LM. The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 2002; 277(29): 25847-50.
32. Van Blitterswijk WJ, van der Luit AH, Veldman RJ, Verheij M, Borst J. Ceramide: second messenger or modulator of membrane structure and dynamics? Biochem J 2003; 369(Pt 2): 199-211.
33. Colombaioni L, Garcia-Gil M. Sphingolipid metabolites in neural signalling and function. Brain Res Brain Res Rev 2004; 46(3): 328-55.
34. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4(8): 604-16.
35. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5(11): 897-907.
36. Degterev A, Boyce M, and Yuan J. A decade of caspases. Oncogene 2003; 22(53): 8543-67.
37. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281(5381): 1312-6.
38. Patel T, Gores GJ, Kaufmann SH. The role of proteases during apoptosis. FASEB J 1996; 10(5): 587-97.
39. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature 2000; 407(6805): 802-9.
40. Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267(5203): 1445-9.
41. Dickson AJ. Apoptosis regulation and its applications to biotechnology. Trends Biotechnol 1998; 16(8): 339-42.
42. Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986; 44(6): 817-29.
43. Jenkins PJ, Bustin SA. Evidence for a link between IGF-I and cancer. Eur J Endocrinol 2004; 151(Suppl 1): S17-22.
44. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003; 107(6): 873-7.
45. Brodt P, Samani A, Navab R. Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol 2000; 60(8): 1101-7.
46. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001; 54(3): 133-7.
47. D'Ercole AJ, Calikoglu AS. Editorial review: the case of local versus endocrine IGF-I actions: the jury is still out. Growth Horm IGF Res 2001; 11(5): 261-5.
48. Federici M, Porzio O, Zucaro L, Giovannone B, Borboni P, Marini MA, et al. Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues. Mol Cell Endocrinol 1997; 129(2): 121-6.
49. Garcia-de Lacoba M, Alarcon C, de la Rosa EJ, de Pablo F. Insulin/ insulin-like growth factor-I hybrid receptors with high affinity for insulin are developmentally regulated during neurogenesis. Endocrinology 1999; 140(1): 233-43.
50. Moss AM, Livingston JN. Distinct beta-subunits are present in hybrid insulin-like growth-factor-1 receptors in the central nervous system. Biochem J 1993; 294 (Pt 3): 685-92.
51. Clairmont KB, Czech MP. Chicken and Xenopus mannose 6-phosphate receptors fail to bind insulin-like growth factor II. J Biol Chem 1989; 264(28): 16390-2.
52. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16(1): 3-34.
53. Ludwig T, Le Borgne R, Hoflack B. Roles for mannose-6-phosphate receptors in lysosomal enzyme sorting, IGF-II binding and clathrin-coat assembly. Trends Cell Biol 1995; 5(5): 202-6.
54. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998; 140(1-2): 19-24.
55. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23(6): 824-54.
56. Bunn RC, Fowlkes JL. Insulin-like growth factor binding protein proteolysis. Trends Endocrinol Metab 2003; 14(4): 176-81.
57. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4(7): 505-18.
58. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 2005; 205(2): 145-53.
59. Lin TC, Yen JM, Gong KB, Hsu TT, Chen LR. IGF-1/IGFBP-1 increases blastocyst formation and total blastocyst cell number in mouse embryo culture and facilitates the establishment of a stem-cell line. BMC Cell Biol 2003; 4(1): 14.
60. Fowden AL. The insulin-like growth factors and feto-placental growth. Placenta 2003; 24(8-9): 803-12.
61. Korgun ET, Dohr G, Desoye G, Demir R, Kayisli UA, Hahn T, et al. Expression of insulin, insulin-like growth factor I and glucocorticoid receptor in rat uterus and embryo during decidualization, implantation and organogenesis. Reproduction 2003; 125(1): 75-84.
62. Miller AG, Aplin JD, Westwood M. Adenovirally mediated expression of insulinlike growth factors enhances the function of first trimester placental fibroblasts. J Clin Endocrinol Metab 2005; 90(1): 379-85.
63. Laviola L, Perrini S, Belsanti G, Natalicchio A, Montrone C, Leonardini A, et al. Intrauterine growth restriction in humans is associated with abnormalities in placental insulin-like growth factor signaling. Endocrinology 2005; 146(3): 1498-505.
64. Fabian D, Il'kova G, Rehak P, Czikkova S, Baran V, Koppel J, et al. Inhibitory effect of IGF-I on induced apoptosis in mouse preimplantation embryos cultured in vitro. Theriogenology 2004; 61(4): 745-55.
65. Zhang J, D'Ercole AJ. Expression of Mcl-1 in cerebellar granule neurons is regulated by IGF-I in a developmentally specific fashion. Brain Res Dev Brain Res 2004; 152(2): 255-63.
66. Popken GJ, Hodge RD, Ye P, Zhang J, Ng W, O'Kusky JR, et al. In vivo effects of insulin-like growth factor-I (IGF-I) on prenatal and early postnatal development of the central nervous system. Eur J Neurosci 2004; 19(8): 2056-68.
67. Bondy CA, Cheng CM. Signaling by insulin-like growth factor 1 in brain. Eur J Pharmacol 2004; 490(1-3): 25-31.
68. Hodge RD, D'Ercole AJ, O'Kusky JR. Insulin-like growth factor-I accelerates the cell cycle by decreasing g1 phase length and increases cell cycle reentry in the embryonic cerebral cortex. J Neurosci 2004; 24(45): 10201-10.
69. Ye P, Popken GJ, Kemper A, McCarthy K, Popko B, D'Ercole AJ, et al. Astrocyte-specific overexpression of insulin-like growth factor-I promotes brain overgrowth and glial fibrillary acidic protein expression. J Neurosci Res 2004; 78(4): 472-84.
70. Gutierrez-Ospina G, Uribe-Querol E, Sanchez N, Geovannini H, Padilla P, Hernandez-Echeagaray E, et al. Similar synapse density in layer IV columns of the primary somatosensory cortex of transgenic mice with different brain size: implications for mechanisms underlying the differential allocation of cortical space. Brain Behav Evol 2004; 64(2): 61-9.
71. Camarero G, Leon Y, Gorospe I, De Pablo F, Alsina B, Giraldez F, et al. Insulin-like growth factor 1 is required for survival of transitamplifying neuroblasts and differentiation of otic neurons. Dev Biol 2003; 262(2): 242-72.
72. Hadsell DL. The insulin-like growth factor system in normal mammary gland function. Breast Dis 2003; 17: 3-14.
73. Stull MA, Wood TL. Expression of the IGFs, IGF-IR and IGFBPs in the normal mammary gland and breast. Breast Dis 2003; 17: 15-26.
74. Boutinaud M, Shand JH, Park MA, Phillips K, Beattie J, Flint DJ, et al. A quantitative RT-PCR study of the mRNA expression profile of the IGF axis during mammary gland development. J Mol Endocrinol 2004; 33(1): 195-207.
75. Modha G, Blanchard A, Iwasiow B, Mao XJ, Troup S, Adeyinka A, et al. Developmental changes in insulin-like growth factor I receptor gene expression in the mouse mammary gland. Endocr Res 2004; 30(1): 127-40.
76. Allar MA, Wood TL. Expression of the insulin-like growth factor binding proteins during postnatal development of the murine mammary gland. Endocrinology 2004; 145(5): 2467-77.
77. Quirk SM, Cowan RG, Harman RM, Hu CL, Porter DA. Ovarian follicular growth and atresia: the relationship between cell proliferation and survival. J Anim Sci 2004; 82(E-Suppl): E40-52.
78. Yu YS, Sui HS, Han ZB, Li W, Luo MJ, Tan JH, et al. Apoptosis in granulosa cells during follicular atresia: relationship with steroids and insulin-like growth factors. Cell Res 2004; 14(4): 341-6.
79. Mao J, Smith MF, Rucker EB, Wu GM, McCauley TC, Cantley TC, et al. Effect of epidermal growth factor and insulin-like growth factor I on porcine preantral follicular growth, antrum formation, and stimulation of granulosal cell proliferation and suppression of apoptosis in vitro. J Anim Sci 2004; 82(7): 1967-75.
80. Wang G, Hardy MP. Development of leydig cells in the insulin-like growth factor-I (igf-I) knockout mouse: effects of igf-I replacement and gonadotropic stimulation. Biol Reprod 2004; 70(3): 632-9.
81. Colao A, Vitale G, Pivonello R, Ciccarelli A, Di Somma C, Lombardi G. et al. The heart: an end-organ of GH action. Eur J Endocrinol 2004; 151(Suppl 1): S93-101.
82. Sacca L, Napoli R, Cittadini A. Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clin Endocrinol (Oxf) 2003; 59(6): 660-71.
83. Herman AC, Carlisle EM, Paxton JB, Gordon PV. Insulin-like growth factor-I governs submucosal growth and thickness in the newborn mouse ileum. Pediatr Res 2004; 55(3): 507-13.
84. Kuemmerle JF, Zhou H, Bowers JG. IGF-I stimulates human intestinal smooth muscle cell growth by regulation of G1 phase cell cycle proteins. Am J Physiol Gastrointest Liver Physiol 2004; 286(3): G412-9.
85. Clemens TL, Chernausek SD. Genetic strategies for elucidating insulin-like growth factor action in bone. Growth Horm IGF Res 2004; 14(3): 195-9.
86. Yakar S, Sun H, Zhao H, Pennisi P, Toyoshima Y, Setser J et al. The growth hormone-insulin like growth factor axis revisited: lessons from IGF-1 and IGF-1 receptor gene targeting. Pediatr Nephrol 2005; 20(3): 251-4.
87. van Kleffens M, Groffen C, Rosato RR, van den Eijnde SM, van Neck JW, Lindenbergh-Kortleve DJ, et al. mRNA expression patterns of the IGF system during mouse limb bud development, determined by whole mount in situ hybridization. Mol Cell Endocrinol 1998; 138(1-2): 151-61.
88. Valverde AM, Benito M. The brown adipose cell: a unique model for understanding the molecular mechanism of insulin resistance. Mini Rev Med Chem 2005; 5(3): 269-78.
89. Pichel JG, Fernandez-Moreno C, Vicario-Abejon C, Testillano PS, Patterson PH, de Pablo F, et al. Developmental cooperation of leukemia inhibitory factor and insulinlike growth factor I in mice is tissue-specific and essential for lung maturation involving the transcription factors Sp3 and TTF-1. Mech Dev 2003; 120(3): 349-61.
90. Han RN, Post M, Tanswell AK, Lye SJ. Insulin-like growth factor-I receptor mediated vasculogenesis/angiogenesis in human lung development. Am J Respir Cell Mol Biol 2003; 28(2): 159-69.
91. Lingohr MK, Buettner R, Rhodes CJ. Pancreatic beta-cell growth and survival--a role in obesity-linked type 2 diabetes? Trends Mol Med 2002; 8(8): 375-84.
92. Kido Y, Nakae J, Hribal ML, Xuan S, Efstratiadis A, Accili D, et al. Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and beta-cell compensation to insulin resistance. J Biol Chem 2002; 277(39): 36740-7.
93. van Haeften TW, Twickler TB. Insulin-like growth factors and pancreas beta cells. Eur J Clin Invest 2004; 34(4): 249-55.
94. Gartner R. Thyroid growth in vitro. Exp Clin Endocrinol 1992; 100(1-2): 32-5.
95. Modric T, Rajkumar K, Murphy LJ. Thyroid gland function and growth in IGF binding protein-1 transgenic mice. Eur J Endocrinol 1999; 141(2): 149-59.
96. Welniak LA, Karas M, Yakar S, Anver MR, Murphy WJ, LeRoith D, et al. Effects of organ-specific loss of insulin-like growth factor-I production on murine hematopoiesis. Biol Blood Marrow Transplant 2004; 10(1): 32-9.
97. Geenen V. The thymic insulin-like growth factor axis: involvement in physiology and disease. Horm Metab Res 2003; 35(11-12): 656-63.
98. Cingel-Ristic V, Flyvbjerg A, Drop SL. The physiological and pathophysiological roles of the GH/IGF-axis in the kidney: lessons from experimental rodent models. Growth Horm IGF Res 2004; 14(6): 418-30.
99. Langlois D, Li JY, Saez JM. Development and function of the human fetal adrenal cortex. J Pediatr Endocrinol Metab 2002; 15 Suppl 5: 1311-22.
100. Oh CD, Chun JS. Signaling mechanisms leading to the regulation of differentiation and apoptosis of articular chondrocytes by insulin-like growth factor-1. J Biol Chem 2003; 278(38): 36563-71.
101. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75(1): 59-72.
102. Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pitts-Meek S, Dalton D, et al. IGF-I is required for normal embryonic growth in mice. Genes Dev 1993; 7(12B): 2609-17.
103. DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990; 345(6270): 78-80.
104. DeChiara TM, Robertson EJ, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991; 64(4): 849-59.
105. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75(1): 73-82.
106. Morrione A, Valentinis B, Xu SQ, Yumet G, Louvi A, Efstratiadis A, et al. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci USA 1997; 94(8): 3777-82.
107. Navarro M, Baserga R. Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor. Endocrinology 2001; 142(3): 1073-81.
108. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999; 19(10): 7203-15.
109. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001; 26(11): 657-64.
110. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKT on multiple fronts. Trends Biochem Sci 2004; 29(5): 233-42.
111. Parsa AT, Holland EC. Cooperative translational control of gene expression by Ras and Akt in cancer. Trends Mol Med 2004; 10(12): 607-13.
112. Heidenreich KA, Zeppelin T, Robinson LJ. Insulin and insulin-like growth factor I induce c-fos expression in postmitotic neurons by a protein kinase C-dependent pathway. J Biol Chem 1993; 268(20): 14663-70.
113. Rosen CJ. Insulin-like growth factor I and bone mineral density: experience from animal models and human observational studies. Best Pract Res Clin Endocrinol Metab 2004; 18(3): 423-35.
114. Sanz C, Leon Y, Canon S, Alvarez L, Giraldez F, Varela-Nieto I, et al. Pattern of expression of the jun family of transcription factors during the early development of the inner ear: implications in apoptosis. J Cell Sci 1999; 112(Pt 22): 3967-74.
115. Camarero G, Avendano C, Fernandez-Moreno C, Villar A, Contreras J, de Pablo F, et al. Delayed inner ear maturation and neuronal loss in postnatal Igf-1-deficient mice. J Neurosci 2001; 21(19): 7630-41.
116. Varela-Nieto I, I, Morales-Garcia JA, Vigil P, Diaz-Casares A, Gorospe I, Sanchez-Galiano S, et al. Trophic effects of insulin-like growth factor-I (IGF-I) in the inner ear. Hear Res 2004; 196(1-2): 19-25.
117. Camarero G, Villar MA, Contreras J, Fernandez-Moreno C, Pichel JG, Avendano C, et al. Cochlear abnormalities in insulin-like growth factor-1 mouse mutants. Hear Res 2002; 170(1-2): 2-11.
118. Frago LM, Canon S, de la Rosa EJ, Leon Y, Varela-Nieto I. Programmed cell death in the developing inner ear is balanced by nerve growth factor and insulin-like growth factor I. J Cell Sci 2003; 116(Pt 3): 475-86.
119. Leon Y, Vazquez E, Sanz C, Vega JA, Mato JM, Giraldez F, et al. Insulin-like growth factor-I regulates cell proliferation in the developing inner ear, activating glycosyl-phosphatidylinositol hydrolysis and Fos expression. Endocrinology 1995; 136(8): 3494-503.
120. Leon Y, Sanz C, Giraldez F, Varela-Nieto I. Induction of cell growth by insulin and insulin-like growth factor-I is associated with Jun expression in the otic vesicle. J Comp Neurol 1998; 398(3): 323-32.
121. Frago LM, Leon Y, de la Rosa EJ, Gomez-Munoz A, Varela-Nieto I. Nerve growth factor and ceramides modulate cell death in the early developing inner ear. J Cell Sci 1998; 111(Pt 5): 549-56.
122. Kopke RD, Jackson RL, Li G, Rasmussen MD, Hoffer ME, Frenz DA, et al. Growth factor treatment enhances vestibular hair cell renewal and results in improved vestibular function. Proc Natl Acad Sci USA 2001; 98(10): 5886-91.
123. Oesterle EC, Tsue TT, Rubel EW. Induction of cell proliferation in avian inner ear sensory epithelia by insulin-like growth factor-I and insulin. J Comp Neurol 1997; 380(2): 262-74.
124. Zine A, van de Water TR. The MAPK/JNK signalling pathway offers potential therapeutic targets for the prevention of acquired deafness. Curr Drug Targets CNS Neurol Disord 2004; 3(4): 325-32.
125. Van De Water TR, Lallemend F, Eshraghi AA, Ahsan S, He J, Guzman J, et al. Caspases, the enemy within, and their role in oxdative stress-induced apoptosis of inner ear sensory cells. Otol Neurotol 2004; 25(4): 627-32.
126. Morishita H, Makishima T, Kaneko C, Lee YS, Segil N, Takahashi K, et al. Deafness due to degeneration of cochlear neurons in caspase-3-deficient mice. Biochem Biophys Res Commun 2001; 284(1): 142-9.
127. Yabu T, Kishi S, Okazaki T, Yamashita M. Characterization of zebrafish caspase-3 and induction of apoptosis through ceramide generation in fish fathead minnow tailbud cells and zebrafish embryo. Biochem J 2001; 360(Pt 1): 39-47.
128. Takahashi K, Kamiya K, Urase K, Suga M, Takizawa T, Mori H, et al. Caspase-3-deficiency induces hyperplasia of supporting cells and degeneration of sensory cells resulting in the hearing loss. Brain Res 2001; 894(2): 359-67.
129. Tuson M, Marfany G, Gonzalez-Duarte R. Mutation of CERKL, a novel human ceramide kinase gene, causes autosomal recessive retinitis pigmentosa (RP26). Am J Hum Genet 2004; 74(1): 128-38.
130. Cecconi F, Roth KA, Dolgov O, Munarriz E, Anokhin K, Gruss P et al. Apaf1-dependent programmed cell death is required for inner ear morphogenesis and growth. Development 2004; 131(9): 2125-35.
131. Ishii N, Wanaka A, Ohno K, Matsumoto K, Eguchi Y, Mori, et al. Localization of bcl-2, bax, and bcl-x mRNAs in the developing inner ear of the mouse. Brain Res 1996; 726(1-2): 123-8.
132. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. et al. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 1993; 90(23): 11217-21.
133. Martin DC, Fowlkes JL, Babic B, Khokha R. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J Cell Biol 1999; 146(4): 881-92.
134. Lopez T, Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002; 1(4): 339-53.
135. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3(5): 298-302.
136. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003; 299(5613): 1753-5.
137. Parrizas M, LeRoith D. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 1997; 138(3): 1355-8.
138. Werner H, Karnieli E, Rauscher FJ, LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 1996; 93(16): 8318-23.
139. Bentov I, LeRoith D, Werner H. The WT1 Wilms' tumor suppressor gene: a novel target for insulin-like growth factor-I action. Endocrinology 2003; 144(10): 4276-9.
140. DeAngelis T, Ferber A, Baserga R. Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor. J Cell Physiol 1995; 164(1): 214-21.
141. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002; 62(4): 1030-5.
142. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 1998; 58(17): 4008-14.
143. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL, et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002; 277(41): 38205-11.
144. Iwatsuki K, Tanaka K, Kaneko T, Kazama R, Okamoto S, Nakayama Y, et al. Runx1 promotes angiogenesis by downregulation of insulin-like growth factor-binding protein-3. Oncogene 2005; 24(7): 1129-37.
145. Laban C, Bustin SA, Jenkins PJ. The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab 2003; 14(1): 28-34.
146. Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B, et al. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol 2005; 229(1-2): 161-73.
147. von Wichert G, Haeussler U, Greten FR, Kliche S, Dralle H, Bohm BO, et al. Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells. Oncogene 2005; 24(7): 1284-9.
148. Secombe J, Pierce SB, Eisenman RN. Myc: a weapon of mass destruction. Cell 2004; 117(2): 153-6.
149. Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W et al. Wnt/ beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets 2004; 4(8): 653-71.
150. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281(5382): 1509-12.
151. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999; 96(4): 1603-8.
152. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci USA 2000; 97(22): 12103-8.
153. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C, et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001; 20(2): 252-9.
154. Andre F, Janssens B, Bruyneel E, van Roy F, Gespach C, Mareel M, et al. Alpha-catenin is required for IGF-I-induced cellular migration but not invasion in human colonic cancer cells. Oncogene 2004; 23(6): 1177-86.
155. LeRoith D, Helman L. The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell 2004; 5(3): 201-2.
156. Resnicoff M, Li W, Basak S, Herlyn D, Baserga R, Rubin R, et al. Inhibition of rat C6 glioblastoma tumor growth by expression ofinsulin-like growth factor I receptor antisense mRNA. Cancer Immunol Immunother1996; 42(1): 64-8.
157. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5(3): 221-30.
158. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of NVP-AEW541 - A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5(3): 231-9.
159. Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 1997; 57(13): 2606-10.
160. Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Torrisi R, Sandri MT, et al. Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Res Treat 2001; 69(1): 21-7.
161. Friend KE. Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Horm IGF Res 2001; 11(Suppl A): S121-3.
162. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
163. Vogt PK. Fortuitous convergences: the beginnings of JUN. Nat Rev Cancer 2002; 2(6): 465-9.
164. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001; 20(19): 2401-12.
165. van Dam H, Castellazzi M. Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene 2001; 20(19): 2453-64.
166. Hartl M, Bader AG, Bister K. Molecular targets of the oncogenic transcription factor jun. Curr Cancer Drug Targets 2003; 3(1): 41-55.
167. Angel P, Hattori K, Smeal T, Karin M. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 1988; 55(5): 875-85.
168. Monnier D, Boutillier AL, Giraud P, Chiu R, Aunis D, Feltz P, et al. Insulin-like growth factor-I stimulates c-fos and c-jun transcription in PC12 cells. Mol Cell Endocrinol 1994; 104(2): 139-45.
169. Umayahara Y Kawamori R, Watada H, Imano E, Iwama N, Morishima T, et al. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 1994; 269(23): 16433-42.
170. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, et al. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 2002; 21(50): 7680-9.
171. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002; 21(15): 4104-13.
172. Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI. Biological and clinical associations of c-jun activation in human breast cancer. Int J Cancer 2000; 89(2): 177-86.
173. Rinehart-Kim J, Johnston M, Birrer M, Bos T. Alterations in the gene expression profile of MCF-7 breast tumor cells in response to c-Jun. Int J Cancer 2000; 88(2): 180-90.
174. Briggs J, Chamboredon S, Castellazzi M, Kerry JA, Bos TJ. Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 2002; 21(46): 7077-91.
175. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, et al. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 1999; 18(44): 6063-70.
176. Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PH, et al. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene 2004; 23(50): 8238-46.
177. Ozanne BW, McGarry L, Spence HJ, Johnston I, Winnie J, Meagher L, et al. Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer 2000; 36(13 Spec No): 1640-8.
178. Black EJ, Clair T, Delrow J, Neiman P, Gillespie DA. Microarray analysis identifies Autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun. Oncogene 2004; 23(13): 2357-66.
179. Iacovoni JS, Cohen SB, Berg T, Vogt PK. v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype. Oncogene 2004; 23(33): 5703-6.
180. Fu S, Bottoli I, Goller M, Vogt PK. Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. Proc Natl Acad Sci USA 1999; 96(10): 5716-21.
181. Bader AG, Schneider ML, Bister K, Hartl M. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1). Oncogene 2001; 20(51): 7524-35.
182. Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK. From the Cover: Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci USA 2005; 102(8): 2703-6.
183. McKnight SL, McBindall--a better name for CCAAT/enhancer binding proteins? Cell 2001; 107(3): 259-61.
184. Wessells J, Yakar S, Johnson PF. Critical prosurvival roles for C/EBP beta and insulin-like growth factor I in macrophage tumor cells. Mol Cell Biol 2004; 24(8): 3238-50.
185. Chang W, Rewari A, Centrella M, McCarthy TL. Fos-related antigen 2 controls protein kinase A-induced CCAAT/enhancer-binding protein beta expression in osteoblasts. J Biol Chem 2004; 279(41): 42438-44.
186. Hartl M, Matt T, Schuler W, Siemeister G, Kontaxis G, Kloiber K, et al. Cell transformation by the v-myc oncogene abrogates c-Myc/Maxmediated suppression of a C/EBP beta-dependent lipocalin gene. J Mol Biol 2003; 333(1): 33-46.
187. Bister K, Jansen HW. Oncogenes in retroviruses and cells: biochemistry and molecular genetics. Adv Cancer Res 1986; 47: 99-188.
188. Grandori C, Eisenman RN. Myc target genes. Trends Biochem Sci 1997; 22(5): 177-81.
189. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999; 19(1): 1-11.
190. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2(10): 764-76.
191. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18(19): 3004-16.
192. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000; 16: 653-99.
193. Eisenman RN. Deconstructing myc. Genes Dev 2001; 15(16): 2023-30.
194. Miltenberger RJ, Sukow KA, Farnham PJ. An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants. Mol Cell Biol 1995; 15(5): 2527-35.
195. Wonsey DR, Zeller KI, Dang CV. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA 2002; 99(10): 6649-54.
196. Mulligan C, Rochford J, Denyer G, Stephens R, Yeo G, Freeman T, et al. Microarray analysis of insulin and insulin-like growth factor-1 (IGF-1)receptor signaling reveals the selective up-regulation of the mitogen heparin-binding EGF-like growth factor by IGF-1. J Biol Chem 2002; 277(45): 42480-7.
197. Dupont J, Dunn SE, Barrett JC, LeRoith D. Microarray analysis and identification of novel molecules involved in insulin-like growth factor-1 receptor signaling and gene expression. Recent Prog Horm Res 2003; 58: 325-42.
198. Rochefort H. Oestrogens, proteases and breast cancer. From cell lines to clinical applications. Eur J Cancer 1994; 30A(10): 1583-6.
199. Kerr LD, Holt JT, Matrisian LM. Growth factors regulate transin gene expression by c-fos-dependent and c-fos-independent pathways. Science 1988; 242(4884): 1424-7.
200. Fowlkes JL, Serra DM, Bunn RC, Thrailkill KM, Enghild JJ, Nagase H. et al. Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I/IGF-binding protein-3 complexes. Endocrinology 2004; 145(2): 620-6.
201. Kim H, Pennie WD, Sun Y, Colburn NH. Differential functional significance of AP-1 binding sites in the promoter of the gene encoding mouse tissue inhibitor of metalloproteinases-3. Biochem J 1997; 324(Pt 2): 547-53.
202. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000; 278(3): 511-5.
203. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003; 22(7): 974-82.
204. Hughes SH, Greenhouse JJ, Petropoulos CJ, Sutrave P. Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors. J Virol 1987; 61(10): 3004-12.
205. Mettouchi A, Cabon F, Montreau N, Vernier P, Mercier G, Blangy D, et al. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J 1994; 13(23): 5668-78.
206. Chen EX, Siu LL. Development of molecular targeted anticancer agents: successes, failures and future directions. Curr Pharm Des 2005; 11(2): 265-72.
207. Ke B, Lipshutz GS, Kupiec-Weglinski JW. Gene therapy in liver ischemia and reperfusion injury. Curr Pharm Des 2006; 12(23): 2969-75.
208. Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des 2005; 11(2): 145-55.